Coverage / LON:FARN / Trade Card

LON:FARN

Faron Pharmaceuticals Oy

OPPORTUNISTIC BUY 2026-08-01 Updated today 42.30p Healthcare - BiotechnologyAWAIT ENTRY
59

Position levels

Currenttoday
42.30p
Buy <=wait / entry
31.67p
Trim >=take some off
65.00p
Thesis breakA negative BEXMAB efficacy or safety readout in HR-MDS/AML that removes bexmaril...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case25%100 / 10025.0
Base case50%62 / 10031.0
Bear case25%10 / 1002.5
Weighted conviction59 / 100 - OPPORTUNISTIC BUY

Top risks

  • Positive EMA opinion on orphan drug designation for bexmarilimab in MDS treatment
  • Final patient identified in BEXMAB phase II dose optimization study for r/r MDS
  • Private placement raising EUR 12 million gross proceeds
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.